New USAN revision policy effective Feb. 1, 2026
Effective Feb. 1, 2026, firms may request one round of revisions to an adoption statement without incurring additional fees. After Feb. 1, 2026, additional revisions must be made by filing a USAN Revised submission, for which there is a fee. The USAN Revised submission must also be filed for revisions requested more than 60 days after the date of adoption. To avoid this additional fee, please list all requested changes on the adoption review form and return this form by the date listed on the statement of adoption.
USAN application submission and fees
To all prospective applicants: USAN application and USAN payments must be submitted electronically through the USAN Application Portal.
To streamline the application process and ensure compliance with current and future FDA and International Nonproprietary Names (INN) policies, USAN applications have been revised. There are now 6 separate application forms. Review the USAN application fee information for each application form (PDF). Once the USAN Council initiates the application review, refunds are no longer possible. Please feel free to contract USAN staff with any questions.
For base and modified forms of a compound
Form A: Single entity drug and salt form is used when requesting a USAN for the base substance and a USAN for the modified (salt) form of a new compound, (for which no USAN exists) to be marketed in the United States. Applicants will receive two separate USAN(s); one for the parent and one for the salt form.
Please note that in the past, because the USAN Program required naming only the form of the compound to be marketed in the United States, and the INN Program names only the parent (base) product, a USAN and INN were often different. To maintain consistency and avoid FDA approval delays if a related substance is later marketed, the USAN Program now requires filing Form A to obtain USAN(s) for the salt and base forms of the compound. The fee associated with this application is $28,000.
For a single entity
Form B: Single entity form is used to request a USAN for a single entity (active moiety, parent compound) for which no modified or salt form will be developed or marketed in the United States. The fee associated with this application is $18,000.
For a modified salt form
Form C: Modified compound form is used to request a USAN for the modified (salt) form of a compound for which a USAN already exists. If a manufacturer finds that they have not requested a USAN for a salt to be marketed, or if they decide to market a different salt than what was named by the USAN Council, they are requested to pursue a USAN for the new salt form using Form C. The fee associated with this application is $10,000.
For a revision to an adopted USAN
Form D: Revise established USAN is used to request a revision to a published, adopted USAN. The fee associated with this application is $5,000.*
*Effective Feb. 1, 2026, firms may request one round of revisions to an adoption statement without incurring additional fees. After Feb. 1, 2026, additional revisions must be made by filing a USAN Revised submission, for which there is a fee. The USAN Revised submission must also be filed for revisions requested more than 60 days after the date of adoption. To avoid this additional fee, please list all requested changes on the adoption review form and return this form by the date listed on the statement of adoption.
For contact lens materials
Form E: Contact lens material form is used to request a USAN for contact lens materials. The fee associated with USAN for new contact lens materials is $18,000. The USANM and USANR fees are $10,000. (Form E is also used to request both USANM and USANR for contact lenses.)
For biologics
Form F: Biologics form is for proteins, peptides, monoclonal antibodies, nucleic acids, all pegylated substances, cell therapies, and gene therapies. Fee for a new monoclonal antibody is $18,000.
Additional application requirements have been established for biologics. Please review these requirements and include with your application materials.
